DISCREPANCY BETWEEN ANALYTIC APPROACHES IN THE CLINICAL AND ECONOMIC EVALUATION OF THE SAME TRIAL- EXPERIENCE IN COPD
Author(s)
Hoogendoorn M, Al M, Rutten-van Mölken MPErasmus University, Rotterdam, Netherlands
OBJECTIVES: Clinical and economic evaluations of the same trial often use different statistical analyses and methods to handle missing data. This leads to different results for the same health outcome. We aimed to study how the combination of multiple imputation (MI) with frequently used advanced methods of clinical analysis affect estimates of cost-effectiveness. METHODS: Data from a two-year RCT of an INTERdisciplinary COMmunity-based COPD management program (INTERCOM) versus usual care were used. Five outcomes, SGRQ, EQ-5D, 6MWD, total and severe exacerbations measured at 4, 12 and 24 months or continuously (exacerbations) were selected. These outcomes were re-analyzed using the same methods used in the clinical paper, i.e. with repeated measurement analysis or negative bionomial regression, but now after missing data have been imputed using MI. The resulting estimates were compared with 1) the estimates in the original clinical paper before MI and 2) the estimates obtained after MI based on simple averages before any further statistical analyses based on maximum likelihood. RESULTS: A total of 175 patients were included in the analysis of which 158 completed the trial. The cost difference of €2751 between INTERCOM and usual care was kept constant. The number of severe exacerbations avoided varied from 0.014 to 0.077 resulting in ICERs from €35,700 to €196,500, depending on the approach used. The improvement in SGRQ ranged from 2.2 to 2.6 units, but the ICERs were all around €1000. The gain in QALYs varied from 0.062 with an ICER of €44,400 to 0.085 with an ICER of €32,400 per QALY gained. The probability that the INTERCOM program was cost-effective at a threshold value of €50,000 ranged from 56% to 74%. CONCLUSIONS: This study showed that the combination of analytic approaches of the clinical and economic evaluations does alter the cost-effectiveness ratios.
Conference/Value in Health Info
2010-11, ISPOR Europe 2010, Prague, Czech Republic
Value in Health, Vol. 13, No. 7 (November 2010)
Code
PRS30
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders